Last reviewed 2026-05-31 · How we verify

Lanatigen C (LANATOSIDE C)

Phase 2 active Small molecule

Lanatigen C (generic name: LANATOSIDE C) is a lanatoside C drug. It is currently in Phase 2 development.

Lanatoside C works by inhibiting the sodium-potassium pump in cardiac cells, leading to increased contractility and reduced heart rate.

Lanatoside C, also known as Lanatigen C, is a small molecule drug in the lanatoside C class. It is a cardiac glycoside that works by inhibiting the sodium-potassium pump in cardiac cells, leading to increased contractility and reduced heart rate. However, due to the lack of available information, its target, approved indications, and commercial status are unknown. Further research is needed to determine its efficacy and safety profile. As a result, it is not possible to provide a comprehensive summary of its key safety considerations.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	LANATOSIDE C
Drug class	lanatoside C
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Imagine your heart cells have a pump that helps them relax and contract. Lanatoside C blocks this pump, making the cells work harder and contract more strongly, which can help improve heart function. However, this can also lead to side effects if not used carefully.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Lanatigen C CI brief — competitive landscape report
Lanatigen C updates RSS · CI watch RSS

Frequently asked questions about Lanatigen C

What is Lanatigen C?

Lanatigen C (LANATOSIDE C) is a lanatoside C drug.

How does Lanatigen C work?

Lanatoside C works by inhibiting the sodium-potassium pump in cardiac cells, leading to increased contractility and reduced heart rate.

What is the generic name of Lanatigen C?

LANATOSIDE C is the generic (nonproprietary) name of Lanatigen C.

What drug class is Lanatigen C in?

Lanatigen C belongs to the lanatoside C class. See all lanatoside C drugs at /class/lanatoside-c.

What development phase is Lanatigen C in?

Lanatigen C is in Phase 2.

Drug class: All lanatoside C drugs
Therapeutic area: All drugs in Cardiovascular

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing